Michael Forer is Vice Chairman of ADC Therapeutics, having previously served as its Chief Executive Officer from formation until June 2015.
Mr. Forer is also Executive Vice President of ADC Therapeutics. He was previously a board member and Executive Director of Spirogen from 2009 up to its sale to AstraZeneca in 2013.
Previously, Mr. Forer was a Managing Director of Auven Therapeutics, a private equity fund focused on the life science sector, and a founding investor in ADC Therapeutics. Mr. Forer was also a co-founder of Rosetta Capital Limited, a London private equity firm focused on the life science sector. Prior to Rosetta, Mr. Forer was an investment manager at Rothschild Asset Management, where he was responsible for making and managing private equity, as well as life science-related investments in North America and Europe. Mr. Forer has also been an active corporate finance and M&A advisor to private and public life science clients.
Mr. Forer has a law degree from the University of British Columbia, a diploma in International Business from the University of Copenhagen, and a Bachelor of Economics from the University of Western Ontario. Mr. Forer is called to the Bar for the Law Society of Upper Canada.